Sign In
Buy ANIX
$2.52
-0.0300 (-1.18%)
At Close: Jun 03, 2026
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer SAN JOSE, Calif., June 1, 2026 /PRNewswire/ -- Anixa Biosciences
Multiple patients have survived substantially beyond expected median survival, including onepatient who survived 28 months and several patients who remain alive with continued follow-up Lira-cel clini
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
09:15am, Friday, 01'st May 2026
SAN JOSE, Calif., May 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today annou
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
09:10am, Wednesday, 29'th Apr 2026
Expands global intellectual property coverage in markets with greater late-stage breast cancerdiagnoses and higher triple-negative breast cancer incidence rates New patent will provide IP protection o
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial SAN JOSE, Calif., April 22, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: AN
Reviewing AVAX Technologies (OTCMKTS:AVXT) & Anixa Biosciences (NASDAQ:ANIX)
01:58am, Monday, 13'th Apr 2026
AVAX Technologies (OTCMKTS:AVXT - Get Free Report) and Anixa Biosciences (NASDAQ: ANIX - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses
Breast cancer vaccine met primary endpoints and generated protocol-defined immuneresponses in 74% of participants in Phase 1 clinical trial Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
08:55am, Tuesday, 07'th Apr 2026
Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in Phase 1 clinical trial Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
09:10am, Monday, 06'th Apr 2026
SAN JOSE, Calif., April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
08:50am, Wednesday, 01'st Apr 2026
Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants SAN JOSE, Calif., April 1, 202
Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial status SAN JOSE, Calif., March 30, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
10:38am, Thursday, 12'th Mar 2026
SAN JOSE, Calif., March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an
Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platform Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and
Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data SAN JOSE, Calif., March 2, 2026 /PRNewswire/ -- Anixa Bioscie
Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology SAN JOSE, Calif., Feb. 23, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a bi
